BERG Announces New Partnership with debra of America to Tackle Epidermolysis Bullosa, a Rare Genetic Tissue Disorder

Biopharmaceutical and Patient Advocacy Group Join Forces to Galvanize the Disease Community and Advance Treatment Research BOSTON, May 15, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced they have entered into a partnership agreement with The Dystrophic Epidermolysis Bullosa Research Association of America (debra of America)…

BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Multiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel

BOSTON, April 3, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced seven poster presentations showing promising preclinical data. This data reflects the impact of BERG’s leading product candidate, BPM 31510, to augment immune responses and potentially improve outcomes of patients suffering from glioblastoma multiforme (GBM), pancreatic…

New Data Published in Nature Medicine from Joslin Diabetes Center Demonstrates the Importance of Interrogating Human Biology

BOSTON, March 27, 2017— BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that the company’s Interrogative Biology® Platform contributed to the discovery of new data using a cold-induced model to promote thermogenesis and facilitate brown fat metabolism. Joslin Diabetes Center led the investigation with BERG providing its Interrogative Biology® platform…

BERG Initiates Phase I/II Monotherapy Trial of BPM 31510-IV in Patients with Glioblastoma Multiforme (GBM)

BOSTON, Feb. 15, 2017 — BERG LLC, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase I/II monotherapy clinical trial for its drug candidate BPM 31510-IV for the potential treatment of glioblastoma multiforme. The compound was guided in development by BERG’s unique AI-based Interrogative Biology® platform that combines…

BERG Enters into Multi-Year Agreement with BD for Next-Generation Analytics in Healthcare IT

Leading Health Companies Combine Health IT Expertise to Advance Patient Health Outcomes BOSTON, Jan. 12, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, announced a multi-year agreement between BERG Analytics, a division of BERG, and BD’s MedMined™ solution.  This new collaboration will leverage the combined healthcare IT expertise of BD…

BERG Presents Data Uncovering a Novel Contributor to Parkinson’s Disease at Society for Neuroscience 2016 Meeting

BERG Presents Data Uncovering a Novel Contributor to Parkinson’s Disease at Society for Neuroscience 2016 Meeting BERG Interrogative Biology® Platform Identifies Potential Contributor to LRRK2-mediated Cell Death in Parkinson’s Disease BOSTON, November 14, 2016 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today unveiled data from a recent study that clarified…

BERG, The Icahn School of Medicine at Mount Sinai to host “Fast Track” event at Fast Company’s Second Annual Innovation Festival 2016

BERG, The Icahn School of Medicine at Mount Sinai to host “Fast Track” event at Fast Company’s Second Annual Innovation Festival 2016 Leading players at the forefront of healthcare innovation will discuss how emerging technologies are delivering on the promise of precision medicine BOSTON – October 31, 2016 — BERG, a biopharmaceutical company uncovering health…

BERG Strengthens Financial Leadership And Expands Board Of Directors

BOSTON, Aug. 17, 2016 /PRNewswire/ — BERG, a technology-based biopharmaceutical company uncovering health solutions through a data-driven, systems biological research approach, today announced an expansion of its Board of Directors, adding three new members who bring a wealth of healthcare, financial and executive leadership to the company. The additions to BERG’s Board of Directors include Shumeet…

BERG Announces Clinical Trial Data Presentations Of BPM 31510 In Advanced Solid Tumors And BPM 31543 For Prevention Of Chemotherapy-Induced Alopecia At American Society of Clinical Oncology Annual Meeting

BOSTON, June 5, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it will present two poster presentations on the Phase 1 study of BPM 31510 (IV) in advanced solid tumors and BPM 31543 for the prevention of chemotherapy-induced alopecia at the American Society of…

BERG Initiates Phase II Combination Trial Of BPM 31510 And Gemcitabine In Patients With Pancreatic Cancer

BOSTON, April 27, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase II clinical trial for its drug candidate BPM 31510 in combination with gemcitabine for the potential treatment of pancreatic cancer. The primary objective of the trial is to evaluate…
1 2